Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Mount Sinai Research Reveals How the Ebola Virus Manages to Evade the Body's Immune Defenses - Mount Sinai
  Tue, 06 Jul 2021 07:00 GMT
• How Ebola virus manages to evade the body's immune defenses - Science Daily
  Wed, 07 Jul 2021 07:00 GMT
• Democratic Republic of the Congo (DRC) - Ebola Situation Report #42 - July 8, 2021 - Democratic Republic of the Congo - ReliefWeb
  Fri, 09 Jul 2021 07:00 GMT
• Republic of Guinea declared End of Second Ebola Virus Disease Outbreak – Africa CDC - africacdc.org
  Sat, 19 Jun 2021 07:00 GMT
• Mechanisms behind Ebola Virus Spread Revealed Ebola virus, illustration - Genetic Engineering & Biotechnology News
  Thu, 08 Jul 2021 07:00 GMT
• UNICEF Guinea Ebola Situation Report No. 8: 2 to 19 June 2021 - Guinea - ReliefWeb
  Mon, 28 Jun 2021 07:00 GMT
• Ebola-Like Pig Illness Pops Up in Germany, Doesn't Pose a Threat to Humans - Gizmodo
  Tue, 20 Jul 2021 20:33 GMT
• Leaving a legacy after Ebola in Guinea - Guinea - ReliefWeb
  Thu, 24 Jun 2021 07:00 GMT
• What is Ebola Virus | Detailed information on Ebola Virus - Times of India
  Wed, 21 Jul 2021 12:46 GMT
• Crucial insight into how Ebola virus evades our immune defenses - Science Daily
  Fri, 25 Jun 2021 07:00 GMT
• Ebola Outbreak in Guinea Declared Over, Officials Say - The Washington Informer
  Wed, 30 Jun 2021 07:00 GMT
• Uncovered: Crucial insight into how Ebola virus evades our immune defenses - EurekAlert
  Thu, 24 Jun 2021 07:00 GMT
• How Ebola Virus Evades the Body's Immune Defenses Revealed - Technology Networks
  Thu, 08 Jul 2021 07:00 GMT
• Crucial Insight on How Ebola Virus Evades Immune Defenses - Technology Networks
  Fri, 25 Jun 2021 07:00 GMT
• Rare Illness Related to Ebola Kills Domestic Pigs: Is It Harmful to Humans? - Nature World News
  Thu, 22 Jul 2021 22:22 GMT

• PRO/AH/EDR> Ebola update (37): research, STAT3 & immune system, lessons, improving response
  Sat, 26 Jun 2021 19:46:55 -0400
  Ebola -- Worldwide/Unknown
  Monash University, Australia, researchers have discovered a key way that one of the world's deadliest pathogens, Ebola virus, evades the immune system. Understanding this process provides new potential targets for the future development of antiviral therapies for a disease that killed over 11 000 people in an outbreak in West Africa between 2014 and 2016, with mortality rates in past outbreaks of 25% to 90%.
  An outbreak of Ebola, for which treatment options are extremely limited, occurred

• Exclusivity of Cultural Practices Within Emerging Disease Outbreak Responses in Developing Nations Leads to Detrimental Outcomes Fri, 23 Jul 2021 06:00:00 -0400
  A number of organizations provide aid and medical care to areas affected by emerging infectious disease outbreaks. This process oftentimes involves organizations traveling to developing areas and coordinating efforts on-site of the initial outbreak. Yet, the longevity and death toll of specific recent outbreaks and inability to effectively control them lead to unnecessary deaths and an unconstructive use of resources. While virtually all organizations justifiably point toward limited resources...
• A framework to support the integration of priority setting in the preparedness, alert, control and evaluation stages of a disease pandemic Thu, 22 Jul 2021 06:00:00 -0400
  The COVID-19 pandemic, where the need-resource gap has necessitated decision makers in some contexts to ration access to life-saving interventions, has demonstrated the critical need for systematic and fair priority setting and resource allocation mechanisms. Disease outbreaks are becoming increasingly common and priority setting lessons from previous disease outbreaks could be better harnessed to inform decision making and planning for future disease outbreaks. The purpose of this paper is to...
• Construction and evaluation of DNA vaccine encoding Ebola virus glycoprotein fused with lysosome-associated membrane protein Sun, 18 Jul 2021 06:00:00 -0400
  Ebola virus (EBOV) of the genus Ebolavirus belongs to the family Filoviridae, which cause disease in both humans and non-human primates. Zaire Ebola virus accounts for the highest fatality rate, reaching 90%. Considering that EBOV has a high infection and fatality rate, the development of a highly effective vaccine has become a top public health priority. Glycoprotein (GP) plays a critical role during infection and protective immune responses. Herein, we developed an EBOV GP recombinant DNA...
• CryoEM structure of the Nipah virus nucleocapsid assembly Fri, 16 Jul 2021 06:00:00 -0400
  Nipah and its close relative Hendra are highly pathogenic zoonotic viruses, storing their ssRNA genome in a helical nucleocapsid assembly formed by the N protein, a major viral immunogen. Here, we report the first cryoEM structure for a Henipavirus RNA-bound nucleocapsid assembly, at 3.5 Å resolution. The helical assembly is stabilised by previously undefined N- and C-terminal segments, contributing to subunit-subunit interactions. RNA is wrapped around the nucleocapsid protein assembly with a...
• Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis Fri, 16 Jul 2021 06:00:00 -0400
  Introduction: The Ebola Virus outbreak in Africa is believed to be one of the deadliest viral infections that causes severe hemorrhagic fever in human and nonhuman primates, which has resulted in increased mortality rates in the affected African countries. Thus, the current study mapped and quantified global research output and trends in the EBOV vaccine publications via a bibliometric analysis.Methods: Publications about the Ebola virus vaccine were extracted from the Web of Science and Scopus...
• Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis Fri, 16 Jul 2021 06:00:00 -0400
  Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety. A total of 21 randomized controlled trial, evaluating seven different vaccines with different doses, and 5,275 participants were analyzed. The rVSVΔG-ZEBOV-GP (2 × 10 ⁷) vaccine was more immunogenic (P-score 0.80). For pain, rVSVΔG-ZEBOV-GP (≤10 ⁵) had few events (P-score...
• Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects Thu, 15 Jul 2021 06:00:00 -0400
  Although substantial progress has been made with Ebola virus (EBOV) vaccine measures, the immune correlates of vaccine-mediated protection remain uncertain. Here, five mucosal vaccine vectors based on human and avian paramyxoviruses provided nonhuman primates with varying degrees of protection, despite expressing the same EBOV glycoprotein (GP) immunogen. Each vaccine produced antibody responses that differed in Fc-mediated functions and isotype composition, as well as in magnitude and coverage...
• A Snapshot of Poverty, Diseases and War - The Democratic Republic of the Congo Thu, 15 Jul 2021 06:00:00 -0400
  DRC's fight with EVD was just settling when WHO declared CoVid-19 to be a PHEIC on Mar 12, 2020. DRC's economic growth decelerated from its pre-COVID level of 4.4% in 2019, to an estimated 0.8% in 2020. This has caused concomitant setbacks in the treatment and control of major health issues like HIV, tuberculosis, measles, rift valley fever and malaria in the country. This coupled with civil unrest, other infectious diseases and risk to the safety of the health workers, this is a recipe for a...
• Health seeking behavior after the 2013-16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone Wed, 14 Jul 2021 06:00:00 -0400
  CONCLUSIONS/SIGNIFICANCE: Analysis of patient demographic data suggests that fewer individuals sought care for Lassa fever and other febrile illnesses in Kenema District after the West African Ebola epidemic. Re-establishing trust in health care services will require efforts beyond rebuilding infrastructure and require concerted efforts to rebuild the trust of local residents who may be wary of seeking healthcare post epidemic.
• Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection Wed, 14 Jul 2021 06:00:00 -0400
  The Ebola virus VP30 protein interacts with the viral nucleoprotein and with host protein RBBP6 via PPxPxY motifs that adopt non-canonical orientations, as compared to other proline-rich motifs. An affinity tag-purification mass spectrometry approach identified additional PPxPxY-containing host proteins hnRNP L, hnRNPUL1 and PEG10, as VP30 interactors. hnRNP L and PEG10, like RBBP6, inhibit viral RNA synthesis and EBOV infection, whereas hnRNPUL1 enhances. RBBP6 and hnRNP L modulate VP30...